HealthPartners Institute, Minneapolis, MN, United States of America.
HealthPartners Institute, Minneapolis, MN, United States of America.
Contemp Clin Trials. 2020 Apr;91:105964. doi: 10.1016/j.cct.2020.105964. Epub 2020 Feb 20.
Cardiovascular (CV) disease is the leading cause of death for people with serious mental illness (SMI), but clinicians are often slow to address this risk.
METHODS/DESIGN: 78 Midwestern primary care clinics were randomized to receive or not receive access to a clinical decision support (CDS) tool. Between March 2016 and September 2018, primary care clinicians (PCPs) received CDS alerts during visits with adult patients with SMI who met minimal inclusion criteria and had at least one CV risk factor not at goal. The PCP CDS included a summary of six modifiable CV risk factors and patient-specific treatment recommendations. Psychiatrists received CDS alerts during their next visit with an eligible patient with SMI that alerted them to an elevated body mass index or recent weight gain and the presence of an obesogenic SMI medication. Study outcomes include total modifiable CV risk, six modifiable CV risk factors, and use of obesogenic SMI medications.
This cluster-randomized pragmatic trial allowed PCPs and psychiatrists the opportunity to improve CV risk in a timely manner for patients with SMI. Effectiveness will be assessed using an intent-to-treat analysis, and outcomes will be assessed largely through electronic health record data harvested by the CDS tool itself. In total, 10,347 patients with SMI had an index primary care visit in a randomized clinic, and 8937 patients had at least one follow-up visit. Analyses are ongoing, and trial results are expected in mid-2020.
ClinicalTrials.gov Identifier: NCT02451670.
心血管疾病是严重精神疾病(SMI)患者的主要死亡原因,但临床医生往往迟迟未能解决这一风险。
方法/设计:78 家中西部初级保健诊所被随机分配接受或不接受临床决策支持(CDS)工具。在 2016 年 3 月至 2018 年 9 月期间,初级保健医生(PCP)在接受符合最低纳入标准且至少有一种未达标的心血管危险因素的 SMI 成年患者就诊时收到 CDS 警报。PCP 的 CDS 包括六个可修改的心血管危险因素摘要和患者特定的治疗建议。在符合条件的 SMI 患者下次就诊时,精神科医生会收到 CDS 警报,提醒他们注意体重指数升高或近期体重增加,以及存在肥胖型 SMI 药物。研究结果包括总可修改的心血管风险、六个可修改的心血管危险因素和肥胖型 SMI 药物的使用。
这项聚类随机实用试验为 PCP 和精神科医生提供了及时改善 SMI 患者心血管风险的机会。将使用意向治疗分析评估有效性,并且主要通过 CDS 工具本身收集的电子健康记录数据评估结果。共有 10347 名 SMI 患者在随机诊所进行了索引初级保健就诊,8937 名患者至少进行了一次随访就诊。分析正在进行中,预计 2020 年年中会得出试验结果。
ClinicalTrials.gov 标识符:NCT02451670。